Michael H Malim Selected Research

Michael H Malim Research Topics

Disease

43	Infections 09/2023 - 08/2002
16	COVID-19 09/2023 - 12/2020
6	Neoplasms (Cancer) 01/2022 - 01/2019
6	Virus Diseases (Viral Diseases) 11/2021 - 08/2002
3	Breakthrough Infections 09/2023 - 01/2022
3	Acquired Immunodeficiency Syndrome (AIDS) 07/2015 - 08/2002
2	Severe Acute Respiratory Syndrome 01/2023 - 01/2021
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 09/2021
2	Necrosis 01/2022 - 09/2021
2	HIV Infections (HIV Infection) 08/2015 - 11/2006
1	Fatigue 05/2023
1	Post-Acute COVID-19 Syndrome 05/2023
1	Type 2 Diabetes Mellitus (MODY) 01/2022
1	Obesity 01/2022
1	Type I Syndactyly 01/2022
1	Pulmonary Embolism 01/2021
1	Reinfection 12/2020
1	Lymphopenia (Lymphocytopenia) 11/2020
1	Inflammation (Inflammations) 07/2015
1	Disease Progression 07/2015
1	Measles 03/2012
1	Mumps 03/2012

Drug/Important Bio-Agent (IBA)

20	Proteins (Proteins, Gene)FDA Link 01/2023 - 08/2002
8	VaccinesIBA 09/2023 - 12/2020
8	Antiviral Agents (Antivirals)IBA 01/2022 - 09/2009
8	CytidineIBA 01/2019 - 04/2005
8	Complementary DNA (cDNA)IBA 01/2018 - 11/2003
7	InterferonsIBA 11/2020 - 10/2013
6	BNT162 VaccineIBA 09/2023 - 01/2021
5	Neutralizing AntibodiesIBA 09/2023 - 12/2020
5	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 06/2003
5	vif Gene ProductsIBA 11/2006 - 08/2002
4	COVID-19 VaccinesIBA 09/2023 - 01/2021
4	Immunoglobulin G (IgG)IBA 01/2022 - 12/2020
4	RNA (Ribonucleic Acid)IBA 01/2021 - 11/2006
4	Interferon Type IIBA 01/2019 - 02/2013
3	AntibodiesIBA 01/2023 - 01/2021
3	APOBEC-1 DeaminaseIBA 12/2011 - 11/2003
2	N-(2-cyanoethylene)urea (BA 1)IBA 09/2023 - 10/2022
2	Interleukin-6 (Interleukin 6)IBA 05/2023 - 11/2020
2	InterleukinsIBA 01/2022 - 09/2021
2	EpitopesIBA 01/2022 - 01/2022
2	Broadly Neutralizing AntibodiesIBA 01/2022 - 06/2021
2	Tumor Necrosis Factor InhibitorsIBA 01/2022 - 09/2021
2	Viral DNAIBA 01/2022 - 03/2004
2	Viral RNAIBA 01/2022 - 01/2022
2	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 09/2021
2	Interleukin-17 (Interleukin 17)IBA 01/2022 - 11/2020
2	mRNA VaccinesIBA 12/2021 - 01/2021
2	Messenger RNA (mRNA)IBA 11/2021 - 11/2006
2	Retroelements (Retrotransposon)IBA 06/2012 - 06/2008
2	Peptides (Polypeptides)IBA 12/2011 - 06/2008
2	Interferon-alpha (Interferon Alfa)IBA 12/2011 - 09/2010
2	PolynucleotidesIBA 03/2009 - 11/2006
2	Viral ProteinsIBA 03/2009 - 11/2006
1	Monoclonal AntibodiesIBA 09/2023
1	Amyloidogenic ProteinsIBA 01/2023
1	Amyloid (Amyloid Fibrils)IBA 01/2023
1	ApolipoproteinsIBA 01/2023
1	Glycoproteins (Glycoprotein)IBA 01/2023
1	Lipoproteins (Lipoprotein)IBA 01/2023
1	HDL LipoproteinsIBA 01/2023
1	Apolipoproteins D (Apo D)IBA 01/2023
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 10/2022
1	Insulin (Novolin)FDA Link 01/2022
1	Interleukin-23 (Interleukin 23)IBA 01/2022
1	ruxolitinibIBA 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	Immune Sera (Antisera)IBA 01/2022
1	Immunoglobulin M (IgM)IBA 01/2022
1	FurinIBA 11/2021
1	Peptide Hydrolases (Proteases)FDA Link 11/2021
1	Niclosamide FDA Link 01/2021
1	AntigensIBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 12/2020
1	Immunoglobulin A (IgA)IBA 12/2020
1	Interleukin-8 (Interleukin 8)IBA 11/2020
1	Interleukin-10 (Interleukin 10)IBA 11/2020
1	Small Interfering RNA (siRNA)IBA 01/2019
1	MutagensIBA 01/2019
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2019
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2019
1	Protein Isoforms (Isoforms)IBA 01/2019
1	Antiviral Restriction FactorsIBA 01/2018
1	UridineIBA 01/2018
1	CytokinesIBA 01/2016
1	Capsid Proteins (Capsid Protein)IBA 01/2016
1	Protein SIBA 08/2015
1	Biomarkers (Surrogate Marker)IBA 07/2015
1	human MX1 proteinIBA 08/2014
1	human MX2 proteinIBA 08/2014
1	triphosphoric acid (triphosphate)IBA 04/2014
1	HydrolasesIBA 04/2014
1	Nuclear Proteins (Protein, Nuclear)IBA 04/2014
1	Dynamins (Dynamin)IBA 10/2013
1	gag Gene Products (gag Protein)IBA 10/2013
1	human APOBEC3 proteinsIBA 09/2008
1	Tryptophan (L-Tryptophan)FDA Link 04/2007

Therapy/Procedure

6	Therapeutics 01/2022 - 08/2002